United States: FDA Releases Work Plan Implementing The 21st Century Cures Act

As the focus on passing user fee legislation continues, the US Food and Drug Administration (FDA) has been moving ahead with implementation of the 21st Century Cures Act (Cures Act), which was enacted in December 2016 following a multi-year, bipartisan effort to accelerate the pace of the discovery, development, and delivery of new treatments and cures.1 Title III of the Cures Act provides the FDA with new authorities aimed at enhancing and accelerating FDA's processes for reviewing and approving new drugs, biologics, and medical devices. The law also authorizes an additional $500 million over 10 years to an FDA Innovation Account to help the Agency carry out these new authorities. 2

On July 7, 2017, FDA made public its Work Plan3 and list of deliverables,4 which provide more detail on how the Agency will allocate the new Innovation Account funds to implement Title III of the Cures Act. Although 37 provisions of the Cures Act are eligible for FDA Innovation Account funds,5 the Agency has initially proposed to limit additional funding to 22 Cures Act provisions, giving priority to provisions that:

  • present the greatest opportunity for the FDA to foster innovation and integrate advances in biological sciences, engineering, information technology, and data science, to most directly improve the Agency's product review tools and processes;
  • address the greatest need for scientific modernization;
  • have the most immediate impact on delivery of services; and
  • have no other source of funding.

As such, certain Cures Act provisions for which FDA has determined that additional funding is not required—such as Secs. 3034 and 3035, which require the FDA to issue guidance and a Congressional report on regenerative therapies—would not receive Innovation Account funds. The FDA, however, plans to take a "flexible approach" to implementing the Cures Act, and will reassess the allocation of Innovation Account funds each appropriations cycle.

This Advisory provides an overview of FDA's proposed allocation of Innovation Account funds from FY 2017 to 2025.

Subtitle A—Patient-Focused Drug Development

The Work Plan proposes allocating a total of $25.8 million from the FDA Innovation Account, over fiscal year (FY) 2018 to FY 2025, to implement the following sections of Subtitle A:

  • Sec. 3001. Patient Experience Data
  • Sec. 3002. Patient-Focused Drug Development Guidance
  • Sec. 3004. Report on Patient Experience Drug Development

These sections require the FDA to issue a statement on patient experience data submitted and reviewed as part of an application, to issue guidance on the collection and use of patient experience data, and to issue a report on the use of patient experience data in regulatory decisionmaking. The Work Plan states that Innovation Account funds would help facilitate a more "systematic gathering" and use of patients' perspectives. FDA proposes strengthening its staff with clinical, statistical, psychometric, and health outcomes research expertise, and incorporating such staff into review teams where sponsors intend to use patient experience data. The Work Plan also describes the development of guidance on patient experience data as a "top priority" for the Agency, though it notes that the FDA intends to primarily rely on Prescription Drug User Fee Act (PDUFA) VI fee funding to support its guidance development work.

Subtitle B—

Advancing New Drug Therapies

FDA proposes allocating a total of $95.3 million of the FDA Innovation Account funds, over FY 2017 through 2025, to implement Subtitle B. The Agency would use the funds to implement the following provisions:

  • Sec. 3001. Qualification of Drug Development Tools. This section requires the Secretary to establish a process for qualification of drug development tools (e.g., biomarkers, clinical outcomes assessments) for use in supporting or obtaining FDA approval for, or investigational use of, a drug or biologic. The Work Plan states that Innovation Account funds would support expert FDA staff and contractors who are needed to help develop the evidentiary criteria to support qualification, development of regulatory informatics platforms, and to integrate new review processes.
  • Sec. 3012. Targeted Drugs for Rare Diseases. This section intends to facilitate the development, review, and approval of "genetically targeted drugs" and "variant protein targeted drugs" that would address an unmet need in one or more patient subgroups with respect to rare diseases or conditions that are serious or life-threatening. This section permits the Secretary to allow the sponsor of a drug or biologic application for a genetically targeted drug or variant protein targeted drug to rely on information previously submitted by the same sponsor, or in limited circumstances another sponsor (i.e., where there is a right of reference), in another application. The Work Plan states that expert FDA staff will be needed to support the review activities.
  • Sec. 3013. Reauthorization of Program to Encourage Treatments for Rare Pediatric Diseases. This section reauthorizes the pediatric rare disease priority review program until 2020. Under the Work Plan, from FY 2018 to 2020, expert FDA staff are needed to develop guidance, review rare pediatric disease designation requests, improve IT and other systems, and to manage the administration of the program.
  • Sec. 3016. Grants for Studying Continuous Manufacturing. This section permits the Secretary to issue grants for the purpose of studying and recommending improvements to the processes of continuous manufacturing for drugs and biological products. Under the Work Plan, expert FDA staff would issue grants and develop well-defined scientific standards and policies for articulating how the Agency would evaluate these technologies as part of submissions for new drugs, generic drugs, biotechnology products, and biosimilars.

Subtitle C—Modern Trial Design and Evidence Development

The Work Plan proposes allocating $57.8 million of the FDA Innovation Account funds, over FY 2017 to 2025, to implement Subtitle C. The Agency would use the funds to implement the following provisions:

  • Sec. 3021. Novel Clinical Trial Designs. This section requires the Secretary to convene a public meeting and to issue guidance for the purpose of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs and biologics. The Work Plan states that FDA expert staff are needed to plan and conduct the public meeting, to further develop novel clinical trial designs and approaches, and to draft the guidance.
  • Sec. 3022. Real World Evidence. This section requires the Secretary to establish a program to evaluate the potential use of "real world evidence" to support approval of a new indication for an already approved drug or to help support or satisfy post-approval study requirements. The Cures Act defines "real world evidence" as "data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than randomized clinical trials." The Work Plan states that FDA staff with expertise in statistics, data science, meta-analysis, clinical outcomes research, and other areas are needed to develop the framework and methodologies for evaluating the use of real world evidence. Such staff would also draft guidance and hold a workshop on using real world evidence in regulatory decisionmaking.
  • Sec. 3023. Protection of Human Research Subjects. This section requires the Secretary to "harmonize" the differences between the HHS Human Subject regulations (Common Rule) and the FDA Human Subject regulations. The Work Plan proposes using staff experienced with the rulemaking and harmonization process to help implement this section.
  • Sec. 3024. Informed Consent Waiver or Alteration for Clinical Investigations. This section gives FDA the authority to waive or alter informed consent requirements for certain clinical trials with "minimal risk." The Work Plan states that the FDA will need highly experienced staff to help revise FDA regulations and to issue guidance.

Subtitle D—Patient Access to Therapies and Information

The Work Plan proposes $185.2 million from the FDA Innovation Account, over FY 2017 to 2025, to implement Subtitle D. Such funds would be used to implement the following sections:

  • Sec. 3031. Summary Level Review. This section permits the Secretary to rely upon "qualified data summaries" to support approval of a supplemental application for a qualified use of a drug or biologic. As the FDA's initial focus in implementing this provision will be on supplemental applications for cancer drugs, the Work Plan proposes that staff in the Oncology Center of Excellence would develop policies and procedures for implementing summary level review for appropriate oncology applications for drugs and biologics.
  • Sec. 3033. Accelerated Approval of Regenerative Advanced Therapies. This section establishes a program under which sponsors could seek Regenerative Medicine Advanced Therapy (RMAT) designation for their products. Upon designation, the sponsor is eligible for earlier interactions with the FDA, and would be eligible for priority review or accelerated approval. The FDA Work Plan states that the Center for Biologics Evaluation and Research (CBER) would need to provide continual RMAT training for all Center staff who work on these products.
  • Sec. 3036. Standards for Regenerative Medicine and Regenerative Advanced Therapies. This section requires the Secretary, in consultation with the National Institute of Standards and Technology and other stakeholders, to develop standards and consensus definition of terms to support the development and review of regenerative medicine therapies and regenerative advanced therapies. The Work Plan proposes using Innovation Account funds to support FDA staff and to facilitate the public collaboration with NIST and other stakeholders. The FDA intends to foster public-private partnerships that would facilitate long-term engagement with stakeholders.
  • Sec. 3038. Combination Product Innovation. This section reforms FDA's approval processes for combination products, including establishing standards for interagency coordination. It also requires FDA to issue guidance on pre-submission interactions between the Agency and sponsors of combination products. To implement this section, the Work Plan states that FDA staff would need to: conduct assessments of existing policies, procedures, and IT systems and make necessary modifications; establish new tracking systems; and support program implementations. Staff would also need to develop and revise guidance documents, regulations, notices, standard operating procedures, trainings, and other tools.

Subtitle F—Medical Device Innovation

The Work Plan proposes allocating $109 million from the FDA Innovation Account, over FY 2017 to 2025, to implement Subtitle F. The funds would be used to implement the following sections of the Cures Act:

  • Sec. 3051. Breakthrough Devices. This section requires the Secretary to establish a pathway for the "efficient and flexible" review of "devices that represent breakthrough technologies." FDA estimates that this program will grow at a rate that could approach 20 percent per year over the next 10 years. As the program requires frequent and extensive interaction between developers and FDA staff during the device development phase, the Work Plan states that the FDA will need to accommodate the increased workload and will need to acquire certain IT systems.
  • Sec. 3052. Humanitarian Device Exemption. This section gives the Secretary the authority to apply the humanitarian device exemption to devices that treat diseases and conditions that affect up to 8,000 individuals in the United States (prior cap was 4,000 individuals). The Work Plan states that FDA staff would be needed to accommodate the increased workload. Additionally, the Agency would need to acquire IT systems and track the impact of this section on the development of devices for rare diseases and conditions.
  • Sec. 3053. Recognition of Standards. This section establishes a process at the FDA for the submission, review, and recognition of standards established by nationally or internationally recognized standards organizations for purposes of medical device review. The Work Plan states that FDA expert staff would be needed to coordinate review of submitted standards and to respond to external information requests. The Agency would also need operating funds to support travel for FDA to participate in a greater number of national and international standard-setting organization meetings.
  • Sec. 3056. Institutional Review Board Flexibility. This section eliminates the requirement that a sponsor of a medical device trial must always use a local institutional review board (IRB). FDA Innovation Account funds would support the development of key guidance documents on the use of centralized IRBs.
  • Sec. 3058. Least Burdensome Device Review. This section requires the FDA to train employees on the meaning and implementation of the least burdensome requirements, and for the Agency to audit the implementation. Funds would be used to support FDA expert staff and contractors to conduct these audits.
  • Sec. 3060. Clarifying Medical Device Software. This section exempts from FDA regulation-specific categories of software based on their low levels of risk to patients. Innovation Account funds would be used to support FDA expert staff in implementing a system for surveillance of exempted products or functions.

Subtitle G—Improving Scientific Experience and Outreach at FDA

The Work Plan proposes allocating $27 million of the FDA Innovation Accounts, from FY 2018 to 2025, to implement Sec. 3073, which requires the FDA to establish one or more Intercenter Institutes for a major disease area or areas. The FDA has already established the first Intercenter Institute—the Oncology Center of Excellence (OCE), which enables a unified policy approach and clinical review of all drugs, biologics, and devices used in medical oncology. The Innovation Funds would support FDA medical and professional staff's coordinated review of oncology product applications across the medical product centers, policy development, and collaboration with external stakeholders.

If you have any questions regarding the implementation of the Cures Act, please do not hesitate to contact us.

Footnotes

1 21st Century Cures Act

2 For an analysis of the 21st Century Cures Act, please view our firm Advisory and webinar, which were released shortly after the law was passed.

3 FDA Work Plan and Proposed Funding Allocation of FDA Innovation Account (June 7, 2017).

4 21st Century Cures Act Deliverables

5 FDA Work Plan and Proposed Funding Allocation of FDA Innovation Account, p. 9.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Akin Gump Strauss Hauer & Feld LLP
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions